Aytu Biopharma (AYTU) Finished Goods (2019 - 2026)

Aytu Biopharma (AYTU) has reported Finished Goods for 8 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Finished Goods fell 52.24% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 52.24% decrease from a year earlier, with the FY2025 full-year figure at $8.9 million, up 45.33% from the prior year.
• Finished Goods was $4.0 million for Q1 2026 at Aytu Biopharma, down from $5.6 million in the prior quarter.
• Over five years, Finished Goods peaked at $9.9 million in Q1 2022 and troughed at $4.0 million in Q1 2026.
• A 5-year average of $7.6 million and a median of $7.7 million in 2023 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods jumped 45.33% in 2025 and slumped 52.24% in 2026, its largest moves.
• Over 5 years, Finished Goods stood at $8.4 million in 2022, then increased by 3.73% to $8.7 million in 2023, then fell by 13.66% to $7.5 million in 2024, then dropped by 24.81% to $5.6 million in 2025, then retreated by 28.22% to $4.0 million in 2026.
• The last three Finished Goods figures came in at $4.0 million (Q1 2026), $5.6 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.